A phase 1/2 of a combination of Cetuximab and Taxane for "triple negative" breast cancer patients

Hovav Nechushtan*, Gilad Vainer, Hana Stainberg, Asher Y. Salmon, Tamar Hamburger, Tamar Peretz

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'A phase 1/2 of a combination of Cetuximab and Taxane for "triple negative" breast cancer patients'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science

Medicine and Dentistry